TVRD Latest Press Releases

-- October 14, 2026 --

Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference Globe Newswire 8:00 AM

-- September 24, 2026 --

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) Globe Newswire 8:00 AM

-- August 26, 2026 --

Tvardi Therapeutics to Participate in Upcoming Investor Events Globe Newswire 8:00 AM

-- August 14, 2026 --

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Globe Newswire 7:00 AM

-- August 12, 2026 --

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 Globe Newswire 8:00 AM

-- July 30, 2026 --

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 Globe Newswire 7:30 AM

-- July 7, 2026 --

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes